Nectin-4 is a cell-adhesion molecule overexpressed in several tumor types, including breast, ovarian, lung, colorectal, pancreatic and urothelial cancer. Enfortumab vedotin (EV), an anti-Nectin-4 ...

Corbus Pharmaceuticals still shows promise, with CRB-701 and CRB-601 advancing in clinical trials. Read why CRBP stock is ...

ADC是肿瘤领域发展最快的治疗方式之一，目前已有15种ADC获批，超过210种正在进行临床试验。近年来，ADC的药物研发进入百花齐放阶段，特别是在HER2、EGFR、Trop2、CLDN18.2、Nectin-4等靶点上展示出显著的疗效和良好的安全性 ...

Completed Enrollment of Dose Escalation Part of Phase 1 Clinical Trial of its Next-Generation Nectin-4 Targeting ADC (CRB-701) - First data ...

Bicycle Therapeutics is a biopharma company targeting unmet medical needs. Discover why BCYC stock benefits from strong ...

Two first-line cutaneous melanoma patients - one patient who was dose escalated from 70 mg to 210 mg and finally to 350 mg experienced a confirmed partial response (PR) at the higher dose; one patient ...

Expands pipeline of T cell engaging bispecific antibodies through acquisitions of CT-95, a Mesothelin x CD3 bispecific ...

Fintel reports that on November 8, 2024, Stephens & Co. initiated coverage of Bicycle Therapeutics plc - Depositary Receipt ( ...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that new preclinical data ...

ADRX-0405 是一种针对 STEAP1 的新型抗体-药物偶联物，1a/b 期研究将研究该药物用于治疗晚期实体瘤。 用于治疗晚期实体肿瘤的下一代 ADC ADRX-0405 的 IND 申请已获得 FDA 批准。 Adcentrx ...

Context Therapeutics Inc. (Nasdaq: CNTX), a clinical-stage biopharmaceutical company, has reported its financial results for ...